Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Location status: Recruiting
NCT Number: NCT06524167
This study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. The study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. Local-regional recurrence free survival is the primary endpoint of the study.
Interested in participating?
Request Info14 year–80 year
All sexes
Observational
Shanghai, 200032, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose.
Time frame: 5 years
Local-regional Recurrence Free Survival
Time frame: 5 years
Disease Control Rate
Time frame: 5 years
Progression Free Survival
Time frame: 5 years
Overall Survival
Time frame: 5 years
Adverse Events
Time frame: 5 years
Quality of Life
Contact information is provided by the study sponsor or research team.
Fudan University
Other
A Real-world Study of Adjuvant Radiotherapy in High Recurrence Risk Locally Advanced Thyroid Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06959511
Endocrine Gland Neoplasms, Endocrine System Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT07124000
Adenocarcinoma, Adenocarcinoma (NOS)
Birmingham, Alabama, United States
View Trial DetailsNCT07707401
Endocrine Gland Neoplasms, Endocrine System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07704658
Advanced Malignancies, Bronchial Neoplasms
Logroño, La Rioja, Spain
View Trial Details